Indication
Myotonic Dystrophy Type 1 (DM1)
4 clinical trials
4 products
1 drug
Product
DYNE-101Clinical trial
A Randomized, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-101 Administered to Participants With Myotonic Dystrophy Type 1Status: Recruiting, Estimated PCD: 2026-07-01
Product
PlaceboClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple-Doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) PatientsStatus: Completed, Estimated PCD: 2023-02-14
Product
AOC 1001Product
VX-670Clinical trial
A Phase 1/2, Randomized, Double-blind, Placebo-controlled Single- and Multiple-dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type 1Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1Status: Not yet recruiting, Estimated PCD: 2026-10-01
Drug
Varlilumab